The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
The Saudi Vaccine and Biomanufacturing Center (SVBC), the first of its kind in the Middle East, broke ground at KAUST on December 15. The center will develop vaccines and biopharmaceutical products under good manufacturing practice (GMP) standards. It is a joint project championed by the Ministry of Energy, Industry and Mineral Resources through the Industrial Clusters Program and supported by KACST. Why it matters: The center will serve as a national platform for pharmaceutical innovation and address epidemic risks in the Kingdom, such as MERS-CoV.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST and Industrial Clusters (IC) virtually signed a Memorandum of Understanding (MoU) to host a National BioPark project in the KAUST Research and Technology Park (KRTP). The BioPark aims to foster research and technology development in biopharmaceutical, smart health, and associated AI technologies. KAUST will provide BioPark entrepreneurs and investors access to its innovation ecosystem and facilities. Why it matters: This initiative will advance Saudi Arabia's biopharmaceutical industry and align with KAUST's focus on biological sciences, smart health, and AI, contributing to economic diversification.
KAUST signed an MoU with MISA and Novo Nordisk at the Riyadh Global Medical Biotechnology Summit 2023. The agreement aims to address healthcare challenges in Saudi Arabia and develop the biotech and pharma sector through knowledge transfer and research. A key objective is to establish a Novo Nordisk Center of Excellence focused on obesity and metabolic research. Why it matters: The partnership will boost Saudi Arabia's Vision 2030 goals of creating tech-driven industries and improving health outcomes through biotechnology.